Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 126 of 6351
-
Could a pill replace chemo for some breast cancer patients?
Disease control OngoingThis is an open-label, multicenter international trial in men and women with primary operable HR+/HER2-, ki67≥20%, grade 2 or 3 and stage II breast cancer to evaluate safety and long-term efficacy of a non-chemo treatment in patients biologically responders to neoadjuvant ribocic…
Phase 2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Simple blood test could spot 20 cancers before symptoms start
Diagnosis Recruiting nowThis is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometria…
Sponsor: Adela, Inc • Aim: Diagnosis
Last updated Jun 27, 2026 08:12 UTC
-
New drug combo aims to extend life in advanced lung cancer
Disease control CompletedResearchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and li…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a drug duo outsmart Treatment-Resistant hodgkin lymphoma?
Disease control Recruiting nowThis phase II trial studies the effect of brentuximab vedotin and nivolumab in treating patients with classic Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory) that have been previously treated with brentuximab vedotin or checkpoint inhi…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
A phone call after the ER: testing a suicide prevention lifeline
Disease control By invitation onlyThe purpose of this study is to evaluate the effectiveness and implementation of a suicide prevention strategy delivered via telehealth in Emergency Departments. We will compare implementation of the Safety Planning Intervention plus follow-up calls (SPI+) delivered by Emergency …
Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a Two-Drug immunotherapy combo outperform standard care in Late-Stage colorectal cancer?
Disease control Stopped earlyThe purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of non-microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR)…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Brain cancer breakthrough? new trial delivers drug straight to tumor
Disease control Recruiting nowPrimary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cance…
Phase 3 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Your phone's mic could detect TB in seconds: new trial recruits 1,751
Diagnosis Recruiting nowTB is the single biggest infectious cause of death (1.5 million died in 2018), killing more HIV-positive people than any other disease, and is arguably the most important poverty-related disease in the world. TB's estimated incidence in Africa has been declining over recent years…
Sponsor: University of Stellenbosch • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
Could whole blood in the ambulance save more trauma patients?
Disease control CompletedOpen label, multi-center, pre-hospital randomized trial utilizing 10 level-1 trauma centers designed to determine the efficacy and safety of low titer whole blood resuscitation as compared to standard of care resuscitation in patients at risk of hemorrhagic shock and to appropria…
Phase 3 • Sponsor: Jason Sperry • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can a triple drug combo outsmart High-Risk CLL?
Disease control Recruiting nowThis multicenter, prospective, open-label, randomized, superiority phase 3 study is designed to demonstrate that treatment with a triple combination of acalabrutinib, obinutuzumab and venetoclax (GAVe) prolong the progression-free survival (PFS) as compared to treatment with the …
Phase 3 • Sponsor: German CLL Study Group • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Lab-Grown heart cells implanted in 10 patients in bid to repair damaged hearts
Disease control OngoingThe purpose of this clinical study is to evaluate the safety and efficacy of HS-001 CS transplanted into severe heart failure patients with underlying ischemic heart disease for 26 weeks after transplantation.
Phase 1/2 • Sponsor: Heartseed Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug duo targets Hard-to-Treat colorectal cancer
Disease control CompletedThe aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipir…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Immunotherapy drug dostarlimab takes on chemo in advanced endometrial cancer trial
Disease control OngoingPhase 3, randomized, multicentre study to evaluate the efficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with MMR deficient relapse or advanced endometrial cancer.
Phase 3 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could a targeted drug delay prostate cancer progression?
Disease control OngoingThe purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could deep brain stimulation break the grip of severe anorexia?
Disease control OngoingThe somatic complications as well as the suicidal risk make Anorexia Nervosa (AN) the psychiatric disease with the highest mortality rate: the standardized mortality ratio is higher than 4 and 1 in 5 patients with AN who dies has committed suicide. Approximately 20% of patients s…
Sponsor: Centre Hospitalier St Anne • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a One-Time gene therapy offer lasting protection for diabetic retinopathy?
Disease control By invitation onlyThis is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of DR with and without center involved-diabetic macular edema (CI-DME) in which they received supra…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Which treatment tames LGS seizures better: surgery or more meds?
Disease control Recruiting nowLennox-Gastaut syndrome is a serious and rare form of epilepsy that begins in infancy and early childhood. Seizures and their consequences need medical attention, emergency encounters, and hospitalizations. Seizures disrupt home life for the patient and for family. Lennox-Gastaut…
Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New mRNA RSV vaccine shows promise for older adults in phase 3 trial
Vaccine CompletedThe main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine (Afluria® Quadrivalent); to evaluate the impact of coadministered influenza vaccine on the immune response to RSV-A…
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 08:07 UTC
-
Immunotherapy combo aims to beat back recurrent nasopharyngeal cancer
Disease control Recruiting nowThis is a multicenter, open-label, randomized, controlled, phase III trial. The purpose of this trial is to evaluate the efficacy and toxicity of anti-PD-1 antibody combined with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed …
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC